Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Regeneron Pharmaceuticals : U.S. Court Dismisses Novartis Patent Infringement Suit Against Regeneron

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/06/2019 | 03:42pm EDT

September 6, 2019

U.S. Court Dismisses Novartis Patent Infringement Suit Against Regeneron

Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN), announced that on September 5, 2019, theU.S. District Court for the Southern District of New York ruled in the company's favor, dismissing the patent infringement suit relating to U.S. Patent No. 5,688,688 (the "'688 Patent") filed by Novartis Vaccines and Diagnostics, Inc., Novartis Pharma AG, and Grifols Worldwide Operations Limited (collectively, Novartis) in 2018. The District Court entered a judgement ofnon-infringementand dismissed with prejudice all of Novartis' claims. This means that the manufacture, sale and marketing of EYLEA®(aflibercept) Injection and ZALTRAP®(ziv-aflibercept)do not infringe the claims of the '688 Patent.

Regeneron is pleased with the U.S. District Court decision, and will continue to vigorously defend against any meritless claims of patent infringement.

Forward-Looking Statements and Use of Digital Media

This communication includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the ultimate outcome of any such proceedings and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the quarterly period ended June 30, 2019. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

1/2

Contacts:

Media Relations

Sarah Cornhill

Tel: +1 (914) 847-5018

Sarah.Cornhill@regeneron.com

Investor Relations

Justin Holko

Tel: +1 (914) 847-7786

Justin.Holko@regeneron.com

2/2

Disclaimer

Regeneron Pharmaceuticals Inc. published this content on 06 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 September 2019 19:41:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
10/18REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
PR
10/10REGENERON PHARMACEUTICALS : to Report Third Quarter 2019 Financial and Operating..
PR
09/23REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Severe Chro..
AQ
09/23REGENERON PHARMACEUTICALS : Lancet Publishes Results from Two Positive Phase 3 T..
AQ
09/23SANOFI : - CHMP recommends approval of Dupixent for severe chronic rhinosinusiti..
AQ
09/20REGENERON PHARMACEUTICALS : The Lancet Publishes Results from Two Positive Phase..
PU
09/20REGENERON PHARMACEUTICALS : Sanofi Get Positive CHMP Opinion for Dupixent
DJ
09/20REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent® (dupilumab) fo..
PR
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/18REGENERON PHARMACEUTICALS : Educational Campaign Helps Teens and Their Caregiver..
PR
More news
Financials (USD)
Sales 2019 7 657 M
EBIT 2019 2 261 M
Net income 2019 1 952 M
Finance 2019 5 857 M
Yield 2019 -
P/E ratio 2019 17,5x
P/E ratio 2020 14,4x
EV / Sales2019 3,53x
EV / Sales2020 3,09x
Capitalization 32 847 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 375,45  $
Last Close Price 300,19  $
Spread / Highest target 65,2%
Spread / Average Target 25,1%
Spread / Lowest Target 2,93%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-19.63%32 847
GILEAD SCIENCES3.77%82 206
VERTEX PHARMACEUTICALS7.25%45 297
WUXI APPTEC CO., LTD.65.51%20 231
GENMAB32.08%13 665
NEUROCRINE BIOSCIENCES, INC.34.13%8 771